Novo Nordisk Warns Customers About Stol... ( PRINCETON N.J. June 13 /- Novo Nordis...)

Novo Nordisk Warns Customers About Stolen Insulin

Date:6/13/2009

PRINCETON, N.J., June 13 /PRNewswire-FirstCall/ -- Novo Nordisk product previously reported as stolen in North Carolina has resurfaced recently at a medical center in Houston.

Three lots of 10 ml vials of insulin, marketed under the brand name Levemir(R) (insulin detemir [rDNA origin] injection), were taken in the original theft and identifiable by the following lot numbers: XZF0036, XZF0037, XZF0038.

A vial or vials of stolen insulin from lot XZF0037 was discovered this week at a medical center in the Houston area. Insulin from these lots did not circulate through the normal Novo Nordisk distribution channel and therefore proper storage conditions for the insulin may not have been followed.

Patients can locate the lot number on the side of the box of insulin or the side of the vial. If a patient finds their insulin is from one of the stolen lots, they should not use the insulin and contact Novo Nordisk Customer Care Center at 1-800-727-6500 for further information and instructions.

The safety of our patients is of paramount concern and we are working with our partners, the pharmacy, the FDA and law enforcement authorities to investigate the situation and take immediate steps to maintain the highest standard of safety and quality for our products.

About Levemir(R) (insulin detemir [rDNA origin] injection)

Levemir(R) is indicated for once- or twice-daily subcutaneous administration for the treatment of adult and pediatric patients with type 1 diabetes mellitus or adult patients with type 2 diabetes mellitus who require basal (long-acting) insulin for the control of hyperglycemia.

Important safety information

Levemir(R) is contraindicated in patients hypersensitive to insulin detemir or one of its excipients.

Hypoglycemia is the most common adverse effect of all insulin therapies, includin
'/>"/>

1

GOOD

Page: 1 2 3
Related medicine news :

1. Novo Nordisk Appoints New Leader of North American Business
2. Novo Nordisk Ranks Supersector Leader in the 2007 Dow Jones Sustainability Indexes
3. Novo Nordisk Settles With Pfizer On Patent Infringement Suit
4. Novo Nordisk Increased Net Profit by 32% in 2007
5. Novo Nordisk Files Annual Report with the SEC
6. Novo Nordisk Consolidates U.S. Diabetes Sales Leadership Under Single Vice President
7. FDA Approves NOVO NORDISKs NovoSeven(R) RT (Coagulation Factor VIIa [Recombinant] Room Temperature Stable) for Hemophilia Patients With Inhibitors
8. Novo Nordisk Changing Diabetes(R) Bus Boogies into San Francisco on World Tour to Beat Diabetes
9. Novo Nordisk Makes its Debut in FORTUNEs 100 Best Companies to Work For
10. Novo Nordisk Appoints Andy Ajello as Vice President for National Diabetes Sales, Managed Care and Government Accounts
11. Photos: Novo Nordisk Improved FlexPen(R) Now Available in the U.S.

Post Your Comments:

Novo Nordisk Warns Customers About Stol...( PRINCETON N.J. June 13 /- Novo Nordis...),Health